Stay updated with the latest news, product updates, research insights, and important announcements from Generic Peptides.
Pemvidutide's 48-Week Data: A Real MASH Contender — or Just Another Phase 2 Headline? What Altimmune Just Showed at EASL On May 28, 2026, at the European Association for the Study of the Liver (EASL) Congress in Barcelona, Altimmune unveiled the full 48-week …
A clear look at how peptide regulation, GLP-1 innovation, and patient access may change the market through 2028.
Something huge is happening with peptides in the US right now. And no, this isn't another TikTok wellness trend. This is a real regulatory shift that could change the game for millions of Americans who've been waiting for safer, legal access to these compounds.
Ozempic and Wegovy are back in supply, but the story is far from over. Learn how FDA changes affect patients, prices, pharmacies, and future GLP-1 access.